Get the Stockscreener App
16.04
6.15%
0.85
Pulse Biosciences Inc stock is traded at $16.04, with a volume of 55,989.
It is up +6.15% in the last 24 hours and up +0.90% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
See More
Previous Close:
$15.19
Open:
$15.23
24h Volume:
55,989
Relative Volume:
0.36
Market Cap:
$992.99M
Revenue:
-
Net Income/Loss:
$-42.21M
P/E Ratio:
-13.15
EPS:
-1.22
Net Cash Flow:
$-33.16M
1W Performance:
-5.37%
1M Performance:
+0.90%
6M Performance:
+106.19%
1Y Performance:
+227.73%
1-Day Range:
$15.13
$16.60
1-Week Range:
$14.06
$18.09
52-Week Range:
$4.571
$22.69
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
Critical Analysis: Pulse Biosciences (NASDAQ:PLSE) and Spectral AI (NASDAQ:MDAI) - Defense World
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2024 Earnings Call Transcript - Insider Monkey
Pulse Biosciences Reports Positive Data From Benign Thyroid Study - MarketWatch
Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association - StockTitan
Pulse Biosciences Appoints David Kenigsberg, M.D. As Chief Medical Officer Of Electrophysiology - citybiz
Pulse Biosciences (NASDAQ:PLSE) Announces Earnings Results - MarketBeat
Pulse Biosciences Inc Reports Q3 2024 GAAP Net Loss of $12.7 Mil - GuruFocus.com
Pulse Biosciences (NASDAQ:PLSE) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat
Pulse Biosciences Inc (PLSE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Pulse Biosciences Reports Q3 2024 Financials and Developments - TipRanks
Pulse Biosciences appoints new electrophysiology CMO - Investing.com
Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results - The Bakersfield Californian
Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology - StockTitan
(PLSE) Trading Report - Stock Traders Daily
Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 7.4%What's Next? - MarketBeat
Pulse Biosciences (PLSE) Scheduled to Post Earnings on Wednesday - MarketBeat
Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024 - StockTitan
Pulse Biosciences (NASDAQ:PLSE) Stock Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
(PLSE) On The My Stocks Page - Stock Traders Daily
Renaissance Technologies LLC Lowers Stock Holdings in Pulse Biosciences, Inc. (NASDAQ:PLSE) - Defense World
Pulse Biosciences (NASDAQ:PLSE) Shares Cross Below 50 Day Moving AverageShould You Sell? - MarketBeat
PLSE MONDAY DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pulse Biosciences, Inc. Investors With Losses Over $100K to Secure Counsel Before Important April 18 Deadline in Securities Class ActionPLSE - AsiaOne
Long Term Trading Analysis for (PLSE) - Stock Traders Daily
Pulse Biosciences (NASDAQ:PLSE) Shares Gap Down to $17.54 - MarketBeat
Pulse Biosciences (NASDAQ:PLSE) Shares Down 5% - MarketBeat
Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 5% - Defense World
Bank of New York Mellon Corp Buys 9,639 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) - Defense World
Pulse Biosciences (NASDAQ:PLSE) Shares Down 5.4% - MarketBeat
Pulse Biosciences Inc [PLSE] Investment Appeal on the Rise - Knox Daily
How To Trade (PLSE) - Stock Traders Daily
Metric Deep Dive: Understanding Pulse Biosciences Inc (PLSE) Through its Ratios - The Dwinnex
Inspire Investing LLC Sells 8,725 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) - Defense World
Pulse Biosciences (NASDAQ:PLSE) Upgraded by StockNews.com to "Sell" - MarketBeat
Pulse Biosciences (NASDAQ:PLSE) Upgraded to “Sell” at StockNews.com - Defense World
Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up to $18.51 - Defense World
Quest Partners LLC Purchases New Shares in Pulse Biosciences, Inc. (NASDAQ:PLSE) - Defense World
Pulse Biosciences (NASDAQ:PLSE) Shares Down 2.7% - Defense World
Keeping an Eye on Pulse Biosciences Inc (PLSE) After Insider Trading Activity - Knox Daily
Pulse Biosciences (NASDAQ:PLSE) Trading Up 7% - MarketBeat
Paul LaViolette Joins Pulse Bioscience's Board Of Directors - MPO-mag
Pulse Biosciences (NASDAQ:PLSE) Trading Down 9.6% - MarketBeat
Pulse Biosciences Inc (PLSE) may enjoy gains as insiders got busy in the recent days - Knox Daily
Ratios in Focus: Analyzing Pulse Biosciences Inc (PLSE)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Pulse Biosciences Inc [PLSE] Investment Guide: What You Need to Know - Knox Daily
(PLSE) Technical Data - Stock Traders Daily
Seborrheic Keratosis Treatment Market Report 2024-2030, Featuring Comprehensive Profiles of Aclaris Therapeutics, Alma Lasers, BIOLASE, BioLineRx, DermBiont, Novartis and Pulse Biosciences - GlobeNewswire
Seborrheic Keratosis Treatment Market Report 2024-2030, Featuring Comprehensive Profiles of Aclaris - Daily Guardian Canada
Pulse Biosciences (NASDAQ:PLSE) Trading Down 8.1% - MarketBeat
Pulse Biosciences (NASDAQ:PLSE) Shares Gap Down to $19.96 - Defense World
Pulse Biosciences (NASDAQ:PLSE) Trading Up 3.9% - MarketBeat
Pulse Biosciences (NASDAQ:PLSE) Stock Quotes, Forecast and News Summary - Benzinga
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pulse Biosciences Inc Stock (PLSE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Director |
Dec 12 '23 |
Buy |
9.15 |
17,999 |
164,691 |
36,984,179 |
| DUGGAN ROBERT W | Director |
Dec 11 '23 |
Buy |
9.36 |
90,118 |
843,504 |
36,966,180 |
| DUGGAN ROBERT W | Director |
Dec 08 '23 |
Buy |
9.54 |
116,656 |
1,112,898 |
36,876,062 |
| DUGGAN ROBERT W | Director |
Dec 07 '23 |
Buy |
9.19 |
74,852 |
687,890 |
36,759,406 |
| DUGGAN ROBERT W | Director |
Dec 06 '23 |
Option Exercise |
5.95 |
9,933 |
59,101 |
36,601,741 |
| DUGGAN ROBERT W | Director |
Dec 06 '23 |
Buy |
9.06 |
82,813 |
750,286 |
36,684,554 |
| DUGGAN ROBERT W | Director |
Dec 05 '23 |
Buy |
9.34 |
66,021 |
616,636 |
351,565 |
| DUGGAN ROBERT W | Director |
Dec 04 '23 |
Option Exercise |
10.66 |
40,347 |
430,099 |
36,591,808 |
| DUGGAN ROBERT W | Director |
Dec 04 '23 |
Buy |
10.38 |
27,000 |
280,260 |
285,544 |
| DUGGAN ROBERT W | Director |
Dec 01 '23 |
Buy |
9.07 |
45,600 |
413,592 |
258,544 |
0.71%
2.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):